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ABSTRACT
Introduction: In the USA, there is a steady rise
of atrial fibrillation due to the aging population
with increased morbidity. This study evaluated
the risk of stroke/systemic embolism (S/SE) and
major bleeding (MB) among elderly patients
with non-valvular atrial fibrillation (NVAF) and
multimorbidity prescribed direct oral anticoagulants (DOACs).
Methods: Using the CMS Medicare database, a
retrospective observational study of adult
patients with NVAF and multimorbidity who
initiated apixaban, dabigatran, or rivaroxaban
from January 1, 2012 to December 31, 2017 was
conducted. High multimorbidity was classified
as having C 6 comorbidities. Cox proportional
hazard models were used to evaluate the hazard
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ratios of S/SE and MB among three 1:1 propensity score matched DOAC cohorts. All-cause
healthcare costs were estimated using generalized linear models.
Results: Overall 36% of the NVAF study population had high multimorbidity, forming three
propensity score matched (PSM) cohorts:
12,511 apixaban-dabigatran, 60,287 apixabanrivaroxaban, and 12,567 dabigatran-rivaroxaban patients. Apixaban was associated with a
lower risk of stroke/SE and MB when compared
with dabigatran and rivaroxaban. Dabigatran
had a lower risk of stroke/SE and a similar risk of
MB when compared with rivaroxaban. Compared to rivaroxaban, apixaban patients incurred lower all-cause healthcare costs, and
dabigatran patients incurred similar all-cause
healthcare costs. Compared to dabigatran,
apixaban patients incurred similar all-cause
healthcare costs.
Conclusion: Patients with NVAF and C 6
comorbid conditions had significantly different
risks for stroke/SE and MB when comparing
DOACs to DOACs, and different healthcare
expenses. This study’s results may be useful for
evaluating the risk–benefit ratio of DOAC use in
patients with NVAF and multimorbidity.
Keywords: Atrial
fibrillation;
Bleeding;
Multimorbidity; Oral anticoagulant; Stroke;
Systemic embolism
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Key Summary Points
Why carry out this study?
This study addresses a knowledge gap in
healthcare cost and effectiveness of oral
anticoagulant therapy among an aging
population with multiple morbidities and
non-valvular atrial fibrillation.
Global estimates of those who have atrial
fibrillation is a population of
approximately 33 million which is
expected to double by 2050.
Because of this growing population, there
is an interest in safe and effective
treatments for patients with non-valvular
atrial fibrillation and multiple
morbidities.
What was learned from the study?
Among direct oral anticoagulants, there
were significant differences in risk and
associated costs for stroke/systemic
embolism and major bleeding.
This study highlights the various risks and
costs of direct oral anticoagulant
treatment in a non-valvular atrial
fibrillation with multimorbidity.

INTRODUCTION
Atrial fibrillation (AF) is the most common
arrhythmia in the USA [1]. Globally, 33 million
people are estimated to have AF, and that
number is expected to double by the year 2050
[2]. In the USA, between 2.7 and 6.1 million
individuals are estimated to have AF, and current projections expect that number to rise to
between 8 and 12 million by the year 2050 [3].
While patients with non-valvular AF (NVAF)
have historically been treated with warfarin,
direct oral anticoagulants (DOACs), including
apixaban, dabigatran, edoxaban, and rivaroxaban, are now recommended in the treatment

guidelines as a non-inferior, safe, and effective
treatment alternative for NVAF [4, 5].
Since NVAF frequently coexists with other
chronic comorbidities (e.g., hypertension, heart
failure, and ischemic heart disease), patients
with AF are frequently categorized as having
multimorbidity, defined as the coexistence of
two or more comorbid conditions [6]. Given the
current aging population, there is a growing
concern regarding increasing patients with
multimorbidity with a reported median number
of six comorbid conditions in these patients [1].
An estimated two-thirds of Medicare patients
are characterized as living with multimorbidity,
and one-third of them having four or more
chronic comorbidities and over 50% having six
or more chronic comorbidities [7]. Multimorbidity in patients with AF has previously been
associated with increased stroke risk (relative to
patients without multimorbidity), worse outcomes after stroke, and lower survival [1, 8].
Despite the need for anticoagulants for NVAF
therapy, they are often underused in the multimorbid population. It has been estimated that
fewer than half of older adults with AF and
multimorbidity (without contraindications) are
prescribed anticoagulants [1].
While there have been studies comparing
DOACs in AF populations, there is a lack of
studies evaluating the effectiveness of DOACs
and healthcare costs in older populations with
multimorbidity (six or more comorbid conditions) [6, 9, 10]. To address this gap in literature,
this study aimed to compare the risk of stroke/
systemic embolism (SE) and major bleeding
(MB) in patients with NVAF and multimorbidity
(six or more comorbid conditions) who initiated a DOAC and the differences in healthcare
costs, including all-cause and outcome-related
healthcare costs.

METHODS
Data Sources and Patient Selection
In this retrospective, observational analysis,
patients with NVAF and multimorbidity who
newly initiated OAC treatments were selected
from Medicare fee-for-service data from the US
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Centers for Medicare & Medicaid Services (CMS)
for the study period of January 1, 2012 to
December 31, 2017.
Patients were included in this analysis if they
had at least one pharmacy claim for apixaban,
dabigatran, rivaroxaban, or edoxaban during
the identification period of January 1, 2013 to
December 31, 2017. The first DOAC pharmacy
claim during the identification period was designated as the index date [11]. At least one AF
diagnosis claim prior to or on the index date

was required for all patients, along with continuous medical and pharmacy health plan
enrollment for at least 12 months prior to the
index date (baseline period). Patients also needed to be at least 65 years of age. Patients prescribed edoxaban were eventually excluded
from the final study population because of
insufficient sample size. Detailed exclusion criteria are listed in Fig. 1. There was no patient
overlap between cohorts as this was an on-

Fig. 1 Patient selection criteria. AF atrial ﬁbrillation, ICD-9/10-CM International Classiﬁcation of Diseases, Ninth/Tenth
Revision, Clinical Modiﬁcation, OAC oral anticoagulant, VTE venous thromboembolism
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Table 1 Chronic health conditions
Coronary artery disease

Hypertension

Musculoskeletal

Renal

Depression or dementia

Heart failure

Valvular disease

Anemia

Cardiovascular disease

Sleep apnea

Chronic liver disease

Hypo-or hyperthyroidism

Gastrointestinal disorder

Malignancy

Peripheral vascular disease

Pulmonary

Diabetes

treatment analysis, and patients were censored
when a switch occurred from their index drug.
Multimorbidity was defined as having concurrent chronic health conditions (Table 1) at
baseline, which represent common conditions
among patients with AF and conditions that
could be related to the outcomes of interest
[12]. Only patients with high multimorbidity
(six or more concurrent chronic health conditions) were included in this analysis to be consistent with the highest risk group in the
literature [1, 7, 8].
Outcome Measures
The primary outcomes of interest were time to
first stroke/SE and time to first MB among
patients with high multimorbidity. Stroke/SE
and MB were identified using hospital claims
that included the outcome as the primary listed
ICD-9-CM or ICD-10-CM diagnosis code.
Stroke/SE was identified as having at least one
stroke/SE event during the follow-up period and
was stratified into three categories: ischemic
stroke, hemorrhagic stroke, and SE. MB was
identified as having at least one MB event during the follow-up period and was also stratified
into three categories: gastrointestinal hemorrhage, intracranial hemorrhage, and other
major bleeding. The secondary outcomes of
interest were follow-up stroke/SE or MB-related
medical costs (per patient per month, PPPM)
and follow-up all-cause healthcare costs (PPPM)
among patients with high multimorbidity.
Stroke/SE and MB-related medical costs were
defined as the costs from the first stroke/SE- and
MB-hospitalization plus all subsequent claims
with a stroke/SE and MB diagnosis, respectively.
The follow-up period started the day after the

index date and continued to the earliest of
30 days after the date of treatment discontinuation, treatment switch, end of continuous
medical and pharmacy enrollment, death, or
end of the study period.
Statistical Analysis
The study population was initially directly
matched on the basis of the level of multimorbidity (low, moderate, high). Subsequently, 1:1
propensity score matching (PSM) was conducted for each comparison group: DOAC vs.
DOAC (apixaban vs. dabigatran, apixaban vs.
rivaroxaban, and dabigatran vs. rivaroxaban)
[11, 12]. The variables used in PSM included
demographics (age, gender, geographic region,
race, Medicaid dual eligibility, part D low
income subsidy), comorbidities (bleeding history, coagulation defects, alcoholism, all conditions in Table 1), and baseline healthcare
utilization (ER visit, inpatient admission). The
nearest neighbor method without replacement,
and a caliper of 0.01 was used to select matched
samples. Furthermore, the balance of covariates
between the matched treatment groups was
determined using an absolute standardized difference of the mean of 0.10 or less [13].
Cumulative incidence rates were illustrated
using Kaplan–Meier curves, and Cox proportional hazard models, with robust sandwich
estimates, were used to assess the risk of stroke/
SE and MB [14]. Treatment groups were included in the Cox models as independent variables, as matched confounders were balanced
after PSM. A p value of 0.05 was used as the
cutoff for statistical significance. All-cause,
stroke/SE, and MB-related costs were evaluated
using
generalized
linear
models
with
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bootstrapping. Two-part models were used for
evaluating stroke/SE and MB-related costs.

information on comorbidities and concomitant
medications are shown in Table 2. Baseline
healthcare utilization and cost are in Table 3.

Ethics Compliance
DOAC vs. DOAC Comparisons
This study was performed in accordance with
the Helsinki Declaration of 1964, and its later
amendments. Since this study did not involve
the collection, use, or transmittal of individually identifiable data, it was deemed exempt
from institutional review board review by
Solutions IRB. Both the data sets and the security of the offices where analysis was completed
(and where the data sets are kept) meet the
requirements of the Health Insurance Portability and Accountability Act of 1996.

RESULTS
After applying the selection criteria, 22.1%
(n = 163,073) of the NVAF population newly
initiated on OACs (n = 737,214) had multimorbidity; 87,436 (53.6%) initiated apixaban,
12,587 (7.7%) dabigatran, and 63,050 (38.7%)
rivaroxaban, (Fig. 1). Before PSM, ages ranged
from 78.1 to 79.6 years, with apixaban patients
being the oldest. CCI, CHA2DS2-VASc, and HASBLED scores ranged from 5.0 to 5.5, 5.7 to 5.8,
and 4.1 to 4.2, respectively, with apixaban
patients having higher CCI, CHA2DS2-VASc,
and HAS-BLED scores compared to dabigatran
and rivaroxaban patients (Supplementary
Table 1).
The unadjusted incidence rates of stroke/SE
per 100 person-years were 1.7 (apixaban), 2.0
(dabigatran), and 1.8 (rivaroxaban). The unadjusted rates for MB per 100 person-years were
6.2 (apixaban), 7.0 (dabigatran), and 9.2
(rivaroxaban).
After PSM, patient pairs were evaluated,
including: 12,511 patient apixaban-dabigatran,
60,287 apixaban-rivaroxaban, and 12,567 dabigatran-rivaroxaban pairs (Fig. 1). The mean
number of comorbidities ranged from 7.6 to 7.7
across the drug cohorts. Coronary artery disease, hypertension, and diabetes mellitus were
among some of the most prevalent comorbid
conditions (Table 2). Initial baseline characteristics of the matched populations and detailed

Compared to rivaroxaban, apixaban was associated with a lower risk of stroke/SE (HR 0.90,
95% CI 0.81–1.00), while dabigatran was associated with a similar risk of stroke/SE (HR 1.04,
95% CI 0.84–1.28). Compared to dabigatran,
apixaban was associated with a lower risk of
stroke/SE (HR 0.71, 95% CI 0.57–0.89). Compared to rivaroxaban, apixaban and dabigatran
were associated with lower risks of MB (HR 0.62,
95% CI 0.59–0.65; HR 0.78, 95% CI 0.71–0.87,
respectively), and apixaban was associated with
a lower risk of MB (HR 0.81, 95% CI 0.72–0.90)
when compared with dabigatran (Fig. 2).
Healthcare Costs
Compared to rivaroxaban, apixaban was associated with lower all-cause hospitalization costs
PPPM ($2371 vs. $2652, p \ 0.001) and all-cause
medical costs PPPM ($3589 vs. $3806,
p \ 0.001) and dabigatran was associated with
similar costs (inpatient: $2448 vs. $2564,
p = 0.330; total medical: $3541 vs. $3729,
p = 0.107). All-cause hospitalization costs PPPM
and all-cause medical costs PPPM were similar
among apixaban when compared to dabigatran
(inpatient: $2344 vs. $2450, p = 0.265; total
medical costs: $3509 vs. $3542, p = 0.711).
Compared to rivaroxaban, apixaban and dabigatran had lower MB-related medical costs
PPPM (apixaban: $209 vs. $309, p \ 0.001;
dabigatran: $240 vs. $294, p = 0.045). MB-related medical costs PPPM were similar for apixaban and dabigatran patients ($192 vs. $241,
p = 0.141). Stroke/SE-related medical costs
PPPM were similar among apixaban ($70 vs.
$69, p = 0.940) and dabigatran ($64 vs. $74,
p = 0.469) when compared with rivaroxaban,
and apixaban when compared with dabigatran
($55 vs. $64, p = 0.562) (Table 4).

6564 (52.5%)

Female

2764 (22.1%)

5036 (40.3%)

1947 (15.6%)

19 (0.2%)

Midwest

South

West

Other

704 (5.6%)

760 (6.1%)

4198 (33.6%)

Nonhispanic
Black

Other

Medicaid
Dual
Eligibility
4207 (33.6%)

753 (6.0%)

674 (5.4%)

11,047 (88.3%) 11,084 (88.6%)

23 (0.2%)

1945 (15.5%)

5016 (40.1%)

2752 (22.0%)

2775 (22.2%)

6500 (52.0%)

6011 (48.0%)

78.2 (7.4)

Dabigatran
cohort
N = 12,511
N/mean (%/
SD)

Nonhispanic
White

Race

2745 (21.9%)

Northeast

US geographic region

5947 (47.5%)

78.2 (7.4)

Male

Gender

Age

Apixaban
cohort
N = 12511
N/mean (%/
SD)

0.15

0.23

1.05

0.93

0.78

0.04

0.33

0.23

0.58

1.02

1.02

0.79

78.8 (7.5)

95 (0.2%)

9837 (16.3%)

3617 (6.0%)

3538 (5.9%)

20,075 (33.3%) 20,432 (33.9%)

3476 (5.8%)

3518 (5.8%)

53,293 (88.4%) 53,132 (88.1%)

73 (0.1%)

9377 (15.6%)

24,996 (41.5%) 25,283 (41.9%)

13,773 (22.8%) 13,435 (22.3%)

12,068 (20.0%) 11,637 (19.3%)

32,227 (53.5%) 32,642 (54.1%)

1.25

0.99

0.14

0.83

0.98

2.08

0.97

1.34

1.80

1.38

1.38

1.08

Rivaroxaban
Standard
cohort
difference
N = 60,287
N/mean (%/SD)

28,060 (46.5%) 27,645 (45.9%)

78.7 (7.5)

Standard Apixaban
difference cohort
N = 60,287
N/mean (%/
SD)

4250 (33.8%)

765 (6.1%)

673 (5.4%)

11,129 (88.6%)

25 (0.2%)

1964 (15.6%)

5023 (40.0%)

2760 (22.0%)

2795 (22.2%)

6514 (51.8%)

6053 (48.2%)

78.1 (7.3)

Dabigatran
cohort
N = 12,567
N/mean (%/
SD)
0.76

Standard
difference

1.96

1.60

2.61

0.36

4349 (34.6%) 1.66

825 (6.6%)

719 (5.7%)

11,023
(87.7%)

23 (0.2%)

2026 (16.1%) 1.35

5117 (40.7%) 1.52

2670 (21.2%) 1.74

2731 (21.7%) 1.23

6512 (51.8%) 0.03

6055 (48.2%) 0.03

78.1 (7.4)

Rivaroxaban
cohort
N = 12,567
N/mean (%/
SD)

Table 2 PSM baseline characteristics of patients prescribed warfarin, apixaban, dabigatran, or rivaroxaban among highly multimorbid patients with AF
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7.6 (1.7)

164 (1.3%)

Alcoholism

6849 (54.7%)

12,352
(98.7%)

Congestive
heart failure

Hypertension

12,313 (98.4%)

6891 (55.1%)

Comorbidities for multimorbidity deﬁnition

221 (1.8%)

1072 (8.6%)

1100 (8.8%)

4.1 (1.1)

Coagulation
defects

4.1 (1.1)

HAS-BLED
score

5.7 (1.5)

3608 (28.8%)

5.7 (1.5)

CHA2DS2VASc score

5.0 (2.6)

Bleeding history 3598 (28.8%)

5.2 (2.7)

Deyo-Charlson
comorbidity
index

Baseline comorbidity

Mean # of
comorbidities

7.6 (1.7)

4583 (36.6%)

Part D low
4575 (36.6%)
income subsidy

ARISTOTLE high multimorbidity

Dabigatran
cohort
N = 12,511
N/mean (%/
SD)

Apixaban
cohort
N = 12511
N/mean (%/
SD)

Table 2 continued

2.63

0.67

3.70

0.79

0.18

1.81

0.00

9.20

0.40

0.13

59,487
(98.7%)

33,125
(54.9%)

1064 (1.8%)

5499 (9.1%)

17,983
(29.8%)

4.2 (1.1)

5.7 (1.5)

5.3 (2.7)

7.6 (1.7)

21,871
(36.3%)

Standard Apixaban
difference cohort
N = 60,287
N/mean (%/
SD)

59,368 (98.5%)

33,241 (55.1%)

1037 (1.7%)

5544 (9.2%)

18,179 (30.2%)

4.1 (1.1)

5.7 (1.5)

5.1 (2.7)

7.7 (1.7)

22,115 (36.7%)

Rivaroxaban
cohort
N = 60,287
N/mean (%/
SD)

1.67

0.39

0.34

0.26

0.71

2.34

0.11

9.09

0.75

0.84

12,367 (98.4%)

6913 (55.0%)

221 (1.8%)

1075 (8.6%)

3619 (28.8%)

4.1 (1.1)

5.7 (1.5)

5.0 (2.6)

7.6 (1.7)

4630 (36.8%)

Standard Dabigatran
difference cohort
N = 12,567
N/mean (%/
SD)

Standard
difference

0.43

0.69

1.91

1.15

1.56

0.54

12,382
(98.5%)

0.97

6896 (54.9%) 0.27

196 (1.6%)

1094 (8.7%)

3745 (29.8%) 2.20

4.1 (1.1)

5.7 (1.5)

5.0 (2.6)

7.6 (1.7)

4749 (37.8%) 1.96

Rivaroxaban
cohort
N = 12,567
N/mean (%/
SD)
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4645 (37.1%)

7481 (59.8%)

4339 (34.7%)

CVD (carotid
stenosis, TIA,
stroke)

Diabetes

Renal (CKD or
CrCl \ 50 ml/
min)

4029 (32.2%)

283.4 (294.3)

165

Low doseb

Follow-up time
(in days)

Median

126

265.6 (320.6)

3543 (28.3%)

8976 (71.7%)

4360 (34.8%)

7550 (60.3%)

4583 (36.6%)

5914 (47.3%)

Dabigatran
cohort
N = 12,511
N/mean (%/
SD)

5.80

9.28

8.47

0.35

1.13

1.03

1.14

161

275.9 (287.7)

20,343
(33.7%)

40,000
(66.3%)

22,516
(37.3%)

35,130
(58.3%)

21,025
(34.9%)

29,145
(48.3%)

Standard Apixaban
difference cohort
N = 60,287
N/mean (%/
SD)

139

271.6 (322.2)

26,695 (44.3%)

34,032 (56.4%)

22,494 (37.3%)

35,105 (58.2%)

21,070 (34.9%)

29,309 (48.6%)

Rivaroxaban
cohort
N = 60,287
N/mean (%/
SD)

1.38

4.69

20.44

0.08

0.08

0.16

0.54

126

265.5 (320.7)

3547 (28.2%)

9028 (71.8%)

4359 (34.7%)

7598 (60.5%)

4607 (36.7%)

5932 (47.2%)

Standard Dabigatran
difference cohort
N = 12,567
N/mean (%/
SD)

0.67

0.37

2.62

0.48

Standard
difference

143

282.9 (334.0)

5.32

5206 (41.4%) 13.29

7451 (59.3%) 26.64

4399 (35.0%)

7575 (60.3%)

4766 (37.9%)

5902 (47.0%)

Rivaroxaban
cohort
N = 12,567
N/mean (%/
SD)

CHA2DS2-VASc congestive heart failure, hypertension, aged C 75 years, diabetes mellitus, prior stroke or transient ischemic attack or thromboembolism, vascular
disease, aged 65–74 years, sex category, CKD chronic kidney disease, CrCI creatinine clearance, HAS-BLED hypertension, abnormal renal or liver function, stroke,
bleeding, labile international normalized ratios, elderly, drugs or alcohol, MI myocardial infarction, NSAIDs non-steroidal anti-inﬂammatory drugs, PAD peripheral
artery disease, PSM propensity score matching, PVD peripheral vascular disease, SD standard deviation, SE systemic embolism
a
Standard dose: 5 mg apixaban, 150 mg dabigatran, 20 mg rivaroxaban
b
Low dose: 2.5 mg apixaban, 75 mg dabigatran, 110 mg dabigatran, 10 mg rivaroxaban, 15 mg rivaroxaban

8490 (67.9%)

Standard dosea

Dose of the index prescription

5843 (46.7%)

Apixaban
cohort
N = 12511
N/mean (%/
SD)

PVD (PAD or
aortic
aneurysm)

Table 2 continued
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0.1 (0.1)

0.6 (0.9)

0.1 (0.1)

2.2 (1.4)

0.1 (0.1)

Number of ER
visits (PPPM)

Number of
outpatient visits
(PPPM)

Number of
inpatient
admission
(PPPM)

Length of inpatient 0.7 (1.0)
stay (in days)
(PPPM)

2.2 (1.3)

0.1 (0.1)

137 (1.1%)

126 (1.0%)

8318 (66.5%)

Any hospice visit

8381 (67.0%)

Any inpatient
admission

12,490
(99.8%)

12,511
(100.0%)

12,482
(99.8%)

Any outpatient
visit

5784 (46.2%)

Dabigatran
cohort
N = 12,511
N/mean (%/
SD)

Any pharmacy visit 12,511
(100.0%)

5740 (45.9%)

Any ER visit

Baseline healthcare utilization

Apixaban
cohort
N = 12,511
N/mean (%/
SD)

4.63

0.77

0.08

0.37

0.86

0.00

1.07

1.43

0.71

0.7 (1.0)

0.1 (0.1)

2.2 (1.4)

0.1 (0.1)

654 (1.1%)

60,287
(100.0%)

42,363
(70.3%)

60,180
(99.8%)

29,400
(48.8%)

Standard Apixaban
difference cohort
N = 60,287
N/mean (%/
SD)

0.7 (1.1)

0.1 (0.1)

2.2 (1.3)

0.1 (0.1)

866 (1.4%)

60,287
(100.0%)

0.41

0.40

3.36

0.58

3.15

0.00

42,460 (70.4%) 0.35

60,197 (99.9%) 0.70

0.6 (0.9)

0.1 (0.1)

2.2 (1.3)

0.1 (0.1)

137 (1.1%)

12,567
(100.0%)

8335 (66.3%)

12,546
(99.8%)

5794 (46.1%)

Standard Dabigatran
difference cohort
N = 12,567
N/mean (%/
SD)

29,311 (48.6%) 0.30

Rivaroxaban
cohort
N = 60,287
N/mean (%/
SD)

0.64

Standard
difference

0.7 (1.0)

0.1 (0.1)

2.2 (1.3)

0.1 (0.1)

172 (1.4%)

12,567
(100.0%)

8365 (66.6%)

3.25

0.53

2.86

1.14

2.53

0.00

0.51

12,545 (99.8%) 0.19

5754 (45.8%)

Rivaroxaban
cohort
N = 12,567
N/mean (%/
SD)

Table 3 PSM baseline healthcare utilization and costs of patients prescribed warfarin, apixaban, dabigatran, or rivaroxaban among highly multimorbid patients with
AF
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$1430
($2128)

$2952
($3163)

$519 ($1052)

$3471
($3363)

All-cause
hospitalization
medical costs

All-cause medical
costs*

Pharmacy costs

All-cause
healthcare costs

4.31

0.37

3.95

$3319 ($3176) 4.64

$480 ($912)

$2839 ($3005) 3.65

$3590
($3395)

$515 ($1036)

$3075
($3191)

$1485
($2108)

$916 ($1180)

2.9 (1.8)

Standard Apixaban
difference cohort
N = 60,287
N/mean (%/
SD)

$1333 ($1904) 4.79

$840 ($1078)

2.9 (1.7)

Dabigatran
cohort
N = 12,511
N/mean (%/
SD)

$3575 ($3440)

$487 ($935)

$3088 ($3289)

$1499 ($2219)

$850 ($1036)

2.9 (1.8)

Rivaroxaban
cohort
N = 60,287
N/mean (%/
SD)

0.44

2.83

0.40

0.61

5.91

0.97

$848 ($1020)

2.9 (1.7)

Rivaroxaban
cohort
N = 12,567
N/mean (%/
SD)

$487 ($1033)
$3315 ($3172) $3430 ($3488)

$480 ($912)

$2835 ($3001) $2943 ($3306)

$1330 ($1902) $1427 ($2312)

$841 ($1078)

2.9 (1.7)

Standard Dabigatran
difference cohort
N = 12,567
N/mean (%/
SD)

3.44

0.70

3.42

4.61

0.71

0.24

Standard
difference

*All-cause medical costs include all-cause ER/outpatient and hospitalization medical costs; all-cause healthcare costs include all-cause medical and pharmacy costs

$887 ($1113)

2.9 (1.7)

Apixaban
cohort
N = 12,511
N/mean (%/
SD)

All-cause ER/
outpatient costs

Baseline costs

Number of
pharmacy visits
(PPPM)

Table 3 continued
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Fig. 2 Incidence rates and hazard ratios of stroke/SE and MB among patients with high multimorbidity receiving DOACs. CI
conﬁdence interval, GI gastrointestinal, HR hazard ratio, ICH intracranial hemorrhage, IR incidence rate, SE systemic embolism

DISCUSSION
To our knowledge, this is the largest cohort of
Medicare patients with NVAF analyzed to evaluate the effectiveness, safety, and healthcare
costs of DOAC treatment among patients with
at least six comorbid conditions. In our analysis,
DOACs were associated with differing risks of
stroke/SE and MB in addition to varying
healthcare costs.
Since multimorbidity is frequently associated
with other comorbidities, multimorbidity is
common in patients with NVAF [15]. The
number of patients with NVAF in the context of
multimorbidity is only expected to increase in
the future. Multimorbidity has previously been
associated with an increased risk of stroke,
bleeding, poor recovery after a stroke, and death
[15]. Our current results are consistent and
reinforce our previous analysis of administrative

claims databases [9]. In that study, we also
included patients from four commercial claims
databases, along with Medicare patients. While
that study found varying risks of stroke/SE and
MB among patients, they found dabigatran to
be associated with a higher risk of stroke/SE
compared to rivaroxaban, while we found similar risk. These differences may have been due to
our Medicare population consisting of older
patients and the longer follow-up in this study.
A prior ARISTOTLE post hoc analysis also found
that multimorbid apixaban patients trended
toward a lower risk of stroke/SE and MB compared to warfarin, which is consistent with the
main trial results [6]. In that study, patients
were classified by the number of comorbidities
into the following groups: as no multimorbidity
(0–2 comorbidities), moderate multimorbidity
(3–5 comorbidities), and high multimorbidity
(at least 6 comorbidities). The risks of stroke/SE

$55

Stroke/SE-related medical costs during followup

a

ER emergency room, PPPM per patient per month, SE
Generalized linear models were used for the analysis of
b
All-cause medical costs include all-cause ER/outpatient
c
All-cause healthcare costs include all-cause medical and

$192
$64

$241

$4245

$3542

$1092

0.562

0.141

0.861

0.711

0.004

0.265

$70

$209

$4313

$3589

$1217

$2371

systemic embolism
all-cause healthcare costs
and hospitalization medical costs
pharmacy costs

$4248

Major bleeding-related medical costs during
follow-up

All-cause healthcare costs

$3509

All-cause medical costsb
c

$1166

All-cause ER/outpatient costs

$2450

$69

$306

$4488

$3806

$1154

$2652

$74

$294

\ 0.001 $240
0.940 $64

$4419

\ 0.001 $4244

$3729

$1165

\ 0.001 $1094
\ 0.001 $3541

$2564

0.469

0.045

0.079

0.107

0.004

0.330

Dabigatran Rivaroxaban P value

\ 0.001 $2448

Apixaban Dabigatran P value Apixaban Rivaroxaban P value

$2344

a

All-cause hospitalization medical costs

Follow-up all-cause healthcare costs

PPPM costs

Table 4 Adjusted healthcare cost comparisons
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and MB were elevated for patients in the high
and moderate multimorbidity groups compared
with the no multimorbidity group.
Few other studies have evaluated the effectiveness of OAC treatment for patients with
NVAF in the context of multimorbidity. A previous study evaluated a cohort of newly diagnosed AF Medicare patients initiating 150 mg
dabigatran, 20 mg rivaroxaban, or warfarin
therapy [10]. Instead of using an actual number
of comorbidities, CHA2DS2VASc, HAS-BLED,
and Gagne comorbidity scores were used as a
proxy for multimorbidity. The authors found
rivaroxaban to be associated with a higher risk
of MB across the three comorbidity scores when
compared to dabigatran, which was consistent
with our results. Any differences in some of our
findings may be due to their use of comorbidity
scores to measure multimorbidity as opposed to
our use of number of comorbidities.
In addition to the enormous healthcare
burden of multimorbid patients, they also carry
a significant economic burden [16, 17]. In our
study, apixaban use was associated with lower
healthcare costs when compared to rivaroxaban
but similar costs when compared to dabigatran.
Our results are partially consistent with those of
a prior Medicare study comparing cost differences between apixaban and other OACs, which
found that apixaban patients were associated
with lower healthcare costs when compared to
dabigatran and rivaroxaban [17]. The differences in our apixaban vs. dabigatran outcomes
may be due to our longer study period
(2012–2019 vs. 2012–2014) and longer mean
follow-up
(265.5–283.4 days
vs.
144.6–185.2 days). Other work using data from the
Department of Defense [18] showed that apixaban had lower cost in patients with NVAF
compared to warfarin ($2277 vs. $2498,
p = 0.148), dabigatran ($2142 vs. $2372,
p = 0.150), and rivaroxaban ($2200 vs. $2546,
p \ 0.001) after PSM. Though our results are
limited to those with multimorbidity they are
consistent with this prior work and observed
differences are due to differences in the data
source used and the inclusion of non-multimorbid patients.
While this study focuses on patients with
multimorbidity, previous subgroup analyses for

renal insufficiency, cancer, and concomitant
use of antiplatelet drugs and NSAIDs among
others have been published [19–21]. Additionally, a systematic literature review found
DOACs to be associated with improved safety
and efficacy in patients with AF and liver cirrhosis [22]. Compared to previous studies, this
study provides a large data set of NVAF Medicare patients over the age of 65 with multimorbidity. The results of this study are
consistent with that of prior real-world evidence
studies in that DOACs are associated with
varying risk profiles.
Limitations
For this retrospective observational study, only
statistical associations could be concluded, not
causal relationships. Although cohorts were
matched through PSM, there were potential
residual confounders. As a result of the nature of
claims studies, outcome measures could only be
based on ICD-9/10-CM codes without further
adjustment with precise clinical criteria. In
addition, clinical data, such as creatinine clearance and weight, were not available in this
administrative claims data source; therefore,
this study was unable to identify appropriate
and inappropriate use of low-dose regimens.
Also, laboratory values, such as hemoglobin, are
not available in the data set.
This study used both the distribution of
comorbidities at baseline and previously published ARISTOTLE trial subgroup analyses to
define multimorbidity, but the definition of
multimorbidity differs from some other studies
and presents a challenge to compare our findings with those of other studies. While all
patients were required to have at least six
comorbidities, the severity of conditions
remained unknown and may not be equal
among patients. Moreover, unobserved heterogeneity may exist across the five data sources.
Finally, the results only reflect the Medicare
multimorbid NVAF population and may not
represent other multimorbid NVAF populations
such as those with commercial insurance.
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CONCLUSION
Patients with NVAF and at least six comorbid
conditions have varying risks for stroke/SE and
MB when comparing DOACs to DOACs. The
observed variation in costs when comparing
DOACs to DOACs indicates another factor that
could be considered when choosing a treatment
for NVAF in the multimorbid population. The
results of this study may be helpful for evaluating the risk–benefit ratio of DOAC use in
patients with NVAF and multimorbidity.
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